Cross-referencing clinical data
Early7,8-Dihydroxyflavone
7,8-Dihydroxyflavone.
A synthetic flavone that mimics BDNF (brain-derived neurotrophic factor), potentially supporting brain plasticity and neuroprotection. Mimics BDNF by binding to TrkB receptors, potentially enhancing brain plasticity, memory formation, and neuroprotection
EarlyResearch strength30mgDaily amount
Reviewed March 2026
- Category
- Compound
- Also filed under
- TrkB receptor agonist (mimics BDNF)Neuroprotective in animal modelsMay support learning and memoryCrosses blood-brain barrier
What 7,8-Dihydroxyflavone is, and what it does.
- Does it work
- The mechanism is fascinating and the animal data is genuinely impressive. But there are zero human clinical trials. You're essentially being your own guinea pig. The nootropic community is enthusiastic, but enthusiasm isn't evidence.
- How much to take
- 10-30mg daily is the common self-experimentation dose. This is entirely based on allometric scaling from animal studies. Nobody actually knows the optimal human dose.
- The first dose
- Some self-experimenters report vivid dreams the first night, which would align with increased neuroplasticity during sleep. Others notice nothing. We genuinely don't know what to expect because nobody's run the trial.
- With regular use
- Unknown in humans. In rodents, chronic administration improved learning and memory over weeks. Whether this translates to humans is pure speculation at this point.
- How well tolerated
- Unknown in humans. The flavone structure is generally considered well tolerated, and related compounds exist in foods. But this specific molecule hasn't been through human safety trials. Oral bioavailability is also questionable.
- How it feels
- Anecdotal reports: vivid dreams, enhanced learning speed, improved mood. But these are from self-selected nootropic enthusiasts, not controlled trials. Take with a boulder of salt.
About 30mg a day is the studied dose.
How much to take a dayLimited data
Up to 10mgA supporting amount. Helps a little, not the studied dose.
10mg to 30mgEnough for most people, and where a lot of good products land.
30mg
The doseThe daily amount the trials actually used. A product at this figure is dosed right where the research is.
Above 30mgMore capsules, not more effect. Rarely in a serving anyway.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Mimics BDNF and activates TrkB receptors
- Improves memory and learning
- Neuroprotective potential
PubMedCochraneClinicalTrials.govNIH ODSSUPP.AILabs test. IngredientMD verifies.PubMedCochraneClinicalTrials.govNIH ODSSUPP.AILabs test. IngredientMD verifies.
Questions people ask about 7,8-Dihydroxyflavone.
- Is this actually safe to take?
- Honest answer: we don't know. No human safety trials exist. Animal studies haven't shown obvious toxicity, and the flavone structure is generally benign. But you're accepting unknown risk. This is experimental territory.
- Why are there no human trials?
- Poor oral bioavailability is the main barrier. The compound doesn't survive digestion well, making it hard to get consistent brain levels. Researchers are developing prodrug versions (R13) that might lead to actual clinical trials.
- Do the animal results mean anything for humans?
- They tell us the mechanism works in mammals. But the translation rate from animal nootropic studies to human efficacy is very low. Many compounds that make mice smarter do nothing for humans.
- What's the oral bioavailability problem?
- 7,8-DHF is rapidly metabolized by liver enzymes and may not reach the brain in sufficient concentrations when taken orally. This is why some people try sublingual administration or co-administration with enzyme inhibitors.
- Should I take this or just exercise?
- Exercise is one of the most potent natural ways to increase BDNF. It's free, well-studied, and has zero unknown risks. If you're not exercising regularly, that's a much better first step than an experimental compound.
- What about the R13 prodrug version?
- R13 is a modified version designed to survive digestion and convert to 7,8-DHF in the brain. It shows better results in animal studies. It's not commercially available as a supplement yet but represents the next generation of this approach.
Nothing to show here, and the reason why.
A pairing appears on this page only when a trial gave both ingredients together and measured the result. 7,8-Dihydroxyflavone has none that clears that bar.
No pairing for 7,8-Dihydroxyflavone has cleared review yet.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
Plays well withEstablished knowledge, not a trial
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
7,8-Dihydroxyflavone + Vitamin B6 pyridoxineDirect enzyme inhibition reported in a published enzymology study: 7,8-dihydroxyflavone inhibits human and murine pyridoxal phosphatase.
Pyridoxal phosphatase removes the phosphate from pyridoxal-5-phosphate, the active B6 vitamer, as part of normal B6 turnover. Inhibiting that phosphatase raises intracellular pyridoxal phosphate independently of any receptor effect. Anyone reading this compound as a purely neurotrophic agent is missing a direct action on vitamin B6 handling, and the pairing deserves to be stated rather than assumed neutral.
7,8-Dihydroxyflavone + P5P active B6The same enzymology, applied to the already-phosphorylated vitamer.
Supplying pyridoxal-5-phosphate directly and simultaneously inhibiting the phosphatase that clears it act on the same pool from two directions. The published work characterised the inhibition in enzyme and cell systems rather than in people, so the human consequence of the combination has not been measured. Read it as a mechanistic flag on a co-formulation, not as a dosing instruction.
7,8-Dihydroxyflavone + Black pepper extract BioPerineEstablished pharmacokinetics: piperine inhibits UDP-glucuronosyltransferase and several CYP enzymes that clear polyphenols.
7,8-Dihydroxyflavone carries a catechol group and is cleared rapidly by glucuronidation, sulfation and catechol-O-methyltransferase, which is why its oral exposure is low. Piperine inhibits the glucuronidation step that handles flavonoids of this class. The same mechanism that raises exposure also raises exposure to anything else sharing that route, which is the trade-off in the pairing.
7,8-Dihydroxyflavone + QuercetinEstablished phase II metabolism shared between flavonoids competing for the same conjugating enzymes.
Quercetin and 7,8-dihydroxyflavone are both flavonoids handled by UGT and sulfotransferase enzymes and by catechol-O-methyltransferase. Taken together they compete for a limited conjugation capacity, so each can slow the other's clearance. This is a pharmacokinetic interaction with no combination trial behind it in this pairing.
7,8-Dihydroxyflavone + LuteolinShared flavone chemistry and shared conjugation routes.
Luteolin is a flavone with its own catechol group on the B ring, handled by the same methylation and glucuronidation machinery. Two catechol-bearing flavonoids taken together compete for catechol-O-methyltransferase capacity. The interaction is metabolic rather than a pooling of effect.
7,8-Dihydroxyflavone + ApigeninShared flavone scaffold and overlapping phase II handling.
Apigenin lacks a catechol group but is still glucuronidated and sulfated along the same route. Co-ingestion divides conjugating capacity between the two flavones. The practical effect is on exposure of each rather than on any shared target.
7,8-Dihydroxyflavone + Sunflower lecithinEstablished formulation chemistry for poorly water-soluble flavonoids.
7,8-Dihydroxyflavone is poorly soluble in water, and dissolution is the first limit on how much is absorbed. Phospholipid complexes and lipid dispersions are the standard formulation answer for flavonoids with this problem. The mechanism is solubility and dispersion, not a change in what the molecule does once absorbed.
7,8-Dihydroxyflavone + MCT oilEstablished absorption physiology for lipophilic polyphenols taken with dietary lipid.
A lipid vehicle keeps a poorly soluble flavonoid dispersed through gastric emptying and supports micellar solubilisation in the small intestine. Medium-chain triglycerides are used for that purpose because they emulsify readily. Effect size for this specific molecule has not been measured in people.
7,8-Dihydroxyflavone + DHAEstablished neurobiology: BDNF and TrkB signalling is one of the routes through which membrane docosahexaenoic acid status is discussed.
DHA is concentrated in neuronal membrane phospholipids and its status has been linked to BDNF and TrkB signalling in preclinical work. 7,8-Dihydroxyflavone is characterised as a small-molecule TrkB agonist. The pairing is a shared-pathway argument built on preclinical evidence and remains mechanistic, not a demonstrated combination effect in people.
7,8-Dihydroxyflavone + Curcumin turmericOverlapping preclinical literature on BDNF signalling plus shared phase II conjugation.
Curcumin is another polyphenol whose preclinical work touches BDNF signalling, and like this flavone it is heavily glucuronidated. The pairing therefore carries both a shared-pathway argument and a competition for conjugating capacity. Neither side of that has been measured in a combination study.
7,8-Dihydroxyflavone + Lions maneOverlapping neurotrophic framing in preclinical literature, through different molecular routes.
Hericium erinaceus compounds are discussed in preclinical work in relation to nerve growth factor rather than BDNF. 7,8-Dihydroxyflavone is characterised against the TrkB receptor. The two are grouped in products by theme rather than by a demonstrated interaction, and no combination data exists.
7,8-Dihydroxyflavone + Bacopa monnieriCommon inclusion in cognition-themed formulations, with distinct mechanisms.
Bacopa's bacosides act through cholinergic and antioxidant routes described in human trials of the herb. This flavone acts on a receptor tyrosine kinase in preclinical models. Co-formulation is a market convention rather than a mechanistic pairing, and it should be labelled as such.
7,8-Dihydroxyflavone + Green tea extract EGCGEstablished competition for catechol-O-methyltransferase between catechol-bearing polyphenols.
EGCG is a catechol-containing polyphenol and a known substrate and inhibitor of catechol-O-methyltransferase. 7,8-Dihydroxyflavone carries its own catechol and is methylated by the same enzyme. Taken together, each slows the other's methylation, raising exposure to both in a way neither product label anticipates.
7,8-Dihydroxyflavone + Vitamin CEstablished redox chemistry of catechols in solution.
Catechol groups oxidise readily to quinones in neutral aqueous solution, which is a stability problem for a dihydroxyflavone in a liquid or a wet formulation. Ascorbate holds the reduced state and is used with catechol-bearing compounds for that reason. The mechanism is formulation stability rather than an effect in the body.
Who should be cautious
Talk to a doctor before taking 7,8-Dihydroxyflavone if any of these apply to you: No human clinical trials, Optimal human dose unknown, Long-term safety not established, Most data from rodent studies. These are flags to check first, not effects 7,8-Dihydroxyflavone is known to cause.
Not medical advice. Show the label to your pharmacist.Getting 7,8-Dihydroxyflavone from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
Tridax procumbens (herb)No meaningful food sources
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
Synthetic 7,8-dihydroxyflavone powderThe neat flavone as a crystalline powder, poorly soluble in water and prone to oxidation of the catechol group when wet.Fits The form used in essentially all published preclinical work and the reference material for identity and assay.Trade-off Low aqueous solubility and rapid conjugation give it modest oral exposure, and the catechol darkens on exposure to air and moisture, which is a real handling and shelf-life consideration.
Cyclodextrin-complexed 7,8-dihydroxyflavoneThe flavone held inside the hydrophobic cavity of a cyclodextrin, which raises apparent aqueous solubility without changing the molecule.Fits Used where a dispersible or liquid presentation is needed and where the neat powder will not wet out.Trade-off The cyclodextrin adds substantial mass per milligram of active, and complexation raises cost and changes dissolution behaviour that any dosing figure must account for.Formulation aid
Phospholipid-dispersed 7,8-dihydroxyflavoneThe flavone dispersed with phosphatidylcholine into a lipid-based delivery system.Fits A conventional approach for poorly soluble polyphenols where the intent is to keep the compound dispersed through gastric transit.Trade-off Lipid systems add excipient mass and can be less physically stable in a dry blend, and no comparative human exposure data exists for this molecule specifically.Formulation aid
What the strongest studies found
The essence, in one line each.
- 7,8-Dihydroxyflavone directly inhibited human and murine pyridoxal phosphatase, raising cellular pyridoxal-5-phosphate, which the authors describe as an activity independent of TrkB.In vitro study. Brenner et al., 2024 (eLife). PMID 38856179 ↗
- Oral dosing was reported to support retinal ganglion cell survival in a preclinical model, with accompanying changes in gut microbial composition and in markers of iron-dependent cell death.Animal study. Zhou et al., 2025 (CNS Neuroscience and Therapeutics). PMID 40365730 ↗
- BDNF-TrkB signalling was reported to support alveolar type 2 epithelial cell survival in a neonatal lung model, with 7,8-dihydroxyflavone named as a TrkB-directed tool compound; the study is about the pathway rather than about the supplement.Animal study. Kuiper-Makris et al., 2025 (American Journal of Respiratory Cell and Molecular Biology). PMID 40198801 ↗
- 7,8-Dihydroxyflavone appeared as one metabolite feature among many in the plasma metabolomic profiles of grazing cattle given tannin supplementation; this is a detected metabolite association, not an administered dose.Animal study. Muzzo et al., 2026 (Journal of Animal Science). PMID 42289986 ↗
These are the studies our verdict leans on, chosen from the 4 we read for 7,8-Dihydroxyflavone. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
